ArticleInvestigational new drugs2016

A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors.

Jeffrey R Infante et al.PubMed ↗Publisher ↗

No numbers read from the abstract.